QIAGEN welcomes approval of Scheme by CELLESTIS Shareholders
Aug 03 2011

QIAGEN welcomes approval of Scheme by CELLESTIS Shareholders

Venlo, The Netherlands, August 3, 2011 - QIAGEN N.V. ("QIAGEN") welcomes the announcement made today by Cellestis Limited ("Cellestis") that Cellestis shareholders have approved QIAGEN's acquisition of all of the ordinary shares in Cellestis shares by way of a scheme of arrangement ("Scheme").

Details of the voting are set out in Cellestis' announcement released earlier today.

"We are delighted by the support shown from Cellestis shareholders today," said Peer Schatz, Chief Executive Officer of QIAGEN N.V. "We believe this will be a good outcome for both sets of shareholders. Cellestis shareholders will realize a very good premium in cash for their shares while the acquisition of Cellestis offers opportunities to create significant value for QIAGEN shareholders."

A court hearing for the approval of the Scheme is expected to be held on Tuesday, 9 August 2011.

If the Court approves the Scheme, it is anticipated that the Implementation Date for the Scheme will be Monday, 29 August 2011.

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs nearly 3,600 people in over 35 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.

FOLLOW US ON SOCIAL MEDIA

Share this page